Chief Healthcare Executive October 22, 2024
Ron Southwick

Robert Califf talked about the difficulties in regulating AI technologies, why he fears AI could exacerbate inequities, and the need for a better supply chain.

Las Vegas – With the growth of artificial intelligence and other technologies evolving so rapidly, Robert Califf says the Food and Drug Administration is going to have to change as well.

The FDA commissioner outlined the challenge during a 20-minute conversation at the HLTH conference Monday.

“We’re entering an era where we’re going to have to rethink everything we do because of the technology changes that we’re seeing, which affect every single industry that we’re dealing with,” Califf said.

The FDA is dealing with the difficulties of the rapid growth in AI technology. As Califf...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Conferences / Podcast, FDA, Govt Agencies, Trends
Related Articles:
FDA updates definition of 'healthy'
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
4 takeaways from the FDA’s first digital health advisory committee
FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight

Share This Article